Nanjing University of Chinese Medicine (NJUCM)   中文版   |   Home   |  Contact Us  
     
 
 
  • Focus01
  • Focus02
  • Focus03
  • Focus04
  • Focus05
 
NJUCM
News
Events
Focus
 
 
Prof. Qin Shukui, Bayi Hospital Affiliated to NJUCM Publishing TAILOR Findings on Journal of Clinical Oncology
 

On September 10, 2018, the globally renowned journal leading in tumor therapy JOURNAL OF CLINICAL ONCOLOGY(IF:26.303)published online a full text of article titled “Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial”, a latest TAILOR findings by Prof. Qin Shukui, Bayi Hospital Affiliated to NJUCM. The article is based on the first phase Ⅲ prospective trial evaluating the efficacy and safety of the first-line cetuximab plus FOLFOX-4 chemotherapy vs FOLFOX-4 chemotherapy alone in patients with RAS wild-type mCRC conducted entirely in China. The trial has revealed that cetuximab plus FOLFOX-4 chemotherapy is safer, more effective for patients with RAS wild-type mCRC. Prof. Qin Shuikui is the first author of the article and the principle investigator of the study. 

Prof. Qin Shukui’s findings proved first-line cetuximab plus FOLFOX-4 chemotherapy as a standard treatment for RAS Wild-Type Metastatic Colorectal Cancer with efficient evidence-based medical proof, clarified the long-time dispute over the clinical efficacy and safety of cetuximab plus FOLFOX-4 chemotherapy, and will be of significant instructive value for standardizing first-line targeted therapy. The findings also became a Chinese own research achievement. 


  Updated:2018-9-12    
ADD:138 Xianlin Rd,Nanjing 210023,P.R.C Tel:(+86)25-85811079 Fax:(+86)25-85811078
All Rights Reserved © Nanjing University of Chinese Medicine